Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258777 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01258777 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 49 participants.
The verdict
NCT01258777, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.
Interventions
- DRUG 400 mg golimumab or placebo
- DRUG 200 mg golimumab or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258777
The ClinicalTrials.gov registry entry for NCT01258777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 400 mg golimumab or placebo is the first listed.
NCT01258777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258777 about?
NCT01258777 is a clinical study titled "A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects". The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.
What is the current status of trial NCT01258777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2010-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01258777?
The interventions under investigation include: 400 mg golimumab or placebo (DRUG), 200 mg golimumab or placebo (DRUG).
Who is sponsoring clinical trial NCT01258777?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.